An in vitro study of dual drug combinations of anti-viral agents, antibiotics, and/or hydroxychloroquine against the SARS-CoV-2 virus isolated from hospitalized patients in Surabaya, Indonesia
Purwati, Andang Miatmoko, Nasronudin, Eryk Hendrianto, Deya Karsari, Aristika Dinaryanti, Nora Ertanti, Igo Syaiful Ihsan, Disca Sandyakala Purnama, Tri Pudy Asmarawati, Erika Marfiani, Yulistiani, Alfian Nur Rosyid, Prastuti Asta Wulaningrum, Herley Windo Setiawan, Imam Siswanto, Ni Nyoman Tri Puspaningsih
PLOS ONE, doi:10.1371/journal.pone.0252302
A potent therapy for the infectious coronavirus disease COVID-19 is urgently required with, at the time of writing, research in this area still ongoing. This study aims to evaluate the in vitro anti-viral activities of combinations of certain commercially available drugs that have recently formed part of COVID-19 therapy. Dual combinatory drugs, namely; Lopinavir-Ritonavir (LOPIRITO)-Clarithromycin (CLA), LOPIRITO-Azithromycin (AZI), LOPIRITO-Doxycycline (DOXY), Hydroxychloroquine (HCQ)-AZI, HCQ-DOXY, Favipiravir (FAVI)-AZI, HCQ-FAVI, and HCQ-LOPIRITO, were prepared. These drugs were mixed at specific ratios and evaluated for their safe use based on the cytotoxicity concentration (CC 50 ) values of human umbilical cord mesenchymal stem cells. The anti-viral efficacy of these combinations in relation to Vero cells infected with SARS-CoV-2 virus isolated from a patient in Universitas Airlangga hospital, Surabaya, Indonesia and evaluated for IC 50 24, 48, and 72 hours after viral inoculation was subsequently determined. Observation of the viral load in qRT-PCR was undertaken, the results of which indicated the absence of high levels of cytotoxicity in any samples and that dual combinatory drugs produced lower cytotoxicity than single drugs. In addition, these combinations demonstrated considerable effectiveness in reducing the copy number of the virus at 48 and 72 hours, while even at 24 hours, post-drug incubation resulted in low IC 50 values. Most combination drugs reduced pro-inflammatory markers, i.e. IL-6 and TNF-α, while increasing the anti-inflammatory response of IL-10. According to these results, the descending order of effective dual combinatory drugs is one of
Competing interests: The authors have declared that no competing interests exist.
Drugs
References
Allen, Balius, Mukherjee, Brozell, Moustakas et al., DOCK 6: Impact of new features and current docking performance, J Comput Chem,
doi:10.1002/jcc.23905Arabi, Deeb, Al-Hameed, Mandourah, Almekhla et al., Macrolides in critically ill patients with middle east respiratory syndrome, Int J Infect Dis,
doi:10.1016/j.ijid.2019.01.041Bacharier, Guilbert, Mauger, Boehmer, Beigelman et al., Early administration of azithromycin and prevention of severe lower respiratory tract illnesses in preschool children with a history of such illnesses: a randomized clinical trial, JAMA
Bacharier, Guilbert, Mauger, Boehmer, Beigelman et al., Early administration of azithromycin and prevention of severe lower respiratory tract illnesses in preschool children with a history of such illnesses: a randomized clinical trial, JAMA,
doi:10.1001/jama.2015.13896Chan, Yao, Yeung, Deng, Bao et al., Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset, J Infect Dis,
doi:10.1093/infdis/jiv392Chu, Cheng, Hung, Wong, Chan et al., Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings, Thorax,
doi:10.1136/thorax.2003.012658Damle, Vourvahis, Wang, Leaney, Corrigan, Clinical pharmacology perspectives on the antiviral activity of azithromycin and use in COVID-19, Clin Pharmacol Ther,
doi:10.1002/cpt.1857Dayer, Old drugs for newly emerging viral disease
Dayer, Taleb-Gassabi, Dayer, Lopinavir; a potent drug against coronavirus infection: insight from molecular docking study, Arch Clin Infect Dis
Devaux, Rolain, Colson, Raoult, New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?, Int J Antimicrob Agents,
doi:10.1016/j.ijantimicag.2020.105938Du, Chen, Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection, Clin Pharmacol Ther,
doi:10.1002/cpt.1844Du, Li, Xia, Ai, Liang et al., Insights into protein-ligand interactions: mechanisms, models, and methods, Int J Mol Sci
Jin, Cai, Cheng, Cheng, Deng et al., A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version), Mil Med Res,
doi:10.1186/s40779-020-0233-6Kg, AluviaH-W-764: Summary of Product Characteristics
Lim, Im, Cho, Bae, Klein et al., Pharmacokinetics of Hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by plasmodium vivax, Antimicrob Agents Chemother,
doi:10.1128/AAC.00339-08Liu, Wan, Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines, J Genet Genomics,
doi:10.1016/j.jgg.2020.02.001Lu, Liu, Yang, Zhao, Wang et al., Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials, Haematologica
Lu, Zhao, Li, Niu, Yang et al., Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding, Lancet,
doi:10.1016/S0140-6736%2820%2930251-8Maier, Martinez, Kasavajhala, Wickstrom, Hauser et al., ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB, J Chem Theory Comput,
doi:10.1021/acs.jctc.5b00255Manusubroto, Wicaksono, Tamba, Sudiharto, Pramusinto et al., Neurosurgery services in Dr. Sardjito General Hospital, Yogyakarta, Indonesia, during COVID-19 pandemic: an experience from a developing country, World Neurosurg,
doi:10.1016/j.wneu.2020.05.124Meng, Zhang, Mezei, Cui, Molecular docking: A powerful approach for structure-based drug discovery, Curr Comput Aided Drug Des,
doi:10.2174/157340911795677602Mennan, Wright, Bhattacharjee, Balain, Richardson et al., Isolation and characterisation of mesenchymal stem cells from different regions of the human umbilical cord, Biomed Res Int,
doi:10.1155/2013/916136Meyerowitz, Vannier, Friesen, Schoenfeld, Gelfand et al., Rethinking the role of hydroxychloroquine in the treatment of COVID-19, FASEB J,
doi:10.1096/fj.202000919Newton, Brockman, Chierakul, Dondorp, Ruangveerayuth et al., Pharmacokinetics of oral doxycycline during combination treatment of severe falciparum malaria, Antimicrob Agents Chemother,
doi:10.1128/AAC.49.4.1622-1625.2005Retallack, Di, Arias, Knopp, Laurie, Zika virus cell tropism in the developing human brain and inhibition by azithromycin, PNAS,
doi:10.1073/pnas.1618029113Rosenberg, Dufort, Udo, Wilberschied, Kumar et al., Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state, JAMA,
doi:10.1001/jama.2020.8630Sahraei, Shabani, Shokouhi, Saffaei, Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine, Int J Antimicrob Agents,
doi:10.1016/j.ijantimicag.2020.105945Sargiacomo, Sotgia, Lisanti, COVID-19 and chronological aging: senolytics and other antiaging drugs for the treatment or prevention of corona virus infection?, Aging,
doi:10.18632/aging.103001Savarino, Boelaert, Cassone, Majori, Cauda, Antiviral effects of chloroquine: Effects of chloroquine on viral infections: an old drug against today's diseases?, Lancet Infect Dis,
doi:10.1016/s1473-3099%2803%2900806-5Singlas, Clinical pharmacokinetics of azithromycin
Toyama, None, Avigan Tablets
Wang, Sun, Yao, Li, Xu et al., Comprehensive evaluation of ten docking programs on a diverse set of protein-ligand complexes: The prediction accuracy of sampling power and scoring power, Phys Chem Chem Phys,
doi:10.1039/c6cp01555gZhu, Zhang, Li, Yang, Song, A novel coronavirus from patients with pneumonia in China, 2019, N Engl J Med,
doi:10.1056/NEJMoa2001017
